Korro Bio, Inc. KRRO

KRRO Company Overview

Korro Bio, Inc. is a clinical-stage biotechnology company focused on the development of RNA-editing medicines designed to treat genetically defined diseases. The company operates within the biotechnology and precision medicine industries, with a strategic emphasis on programmable RNA editing through endogenous adenosine deaminase acting on RNA (ADAR) enzymes. Korro Bio’s core technology platform, commonly referred to as OPERA, is intended to selectively edit RNA transcripts without permanently altering DNA, positioning the company within the emerging field of RNA therapeutics alongside broader gene-editing and nucleic acid medicine developers.

The company’s primary value drivers are its proprietary RNA-editing platform, internal therapeutic pipeline, and strategic pharmaceutical collaborations. Korro Bio has concentrated its development efforts on rare diseases and conditions with clear genetic drivers, particularly in liver-related and metabolic indications. The company traces its origins to research advances in RNA editing and later became publicly traded through a merger transaction involving Frequency Therapeutics in 2023, after which the combined entity adopted the Korro Bio name and ticker symbol KRRO.